BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 22961713)

  • 1. Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma.
    Sieghart W; Pinter M; Hucke F; Graziadei I; Schöniger-Hekele M; Müller C; Vogel W; Trauner M; Peck-Radosavljevic M
    Hepatology; 2013 Jun; 57(6):2224-34. PubMed ID: 22961713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma.
    Sieghart W; Hucke F; Pinter M; Graziadei I; Vogel W; Müller C; Heinzl H; Trauner M; Peck-Radosavljevic M
    Hepatology; 2013 Jun; 57(6):2261-73. PubMed ID: 23316013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum C-reactive protein levels predict survival in hepatocellular carcinoma.
    Nagaoka S; Yoshida T; Akiyoshi J; Akiba J; Torimura T; Adachi H; Kurogi J; Tajiri N; Inoue K; Niizeki T; Koga H; Imaizumi T; Kojiro M; Sata M
    Liver Int; 2007 Oct; 27(8):1091-7. PubMed ID: 17845537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma.
    Waidmann O; Köberle V; Bettinger D; Trojan J; Zeuzem S; Schultheiß M; Kronenberger B; Piiper A
    J Hepatol; 2013 Oct; 59(4):769-79. PubMed ID: 23792028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The addition of C-reactive protein to validated staging systems improves their prognostic ability in patients with hepatocellular carcinoma.
    Kinoshita A; Onoda H; Imai N; Iwaku A; Oishi M; Tanaka K; Fushiya N; Koike K; Nishino H; Matsushima M; Tajiri H
    Oncology; 2014; 86(5-6):308-17. PubMed ID: 24924697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma.
    An HJ; Jang JW; Bae SH; Choi JY; Yoon SK; Lee MA; You YK; Kim DG; Jung ES
    Liver Transpl; 2012 Dec; 18(12):1406-14. PubMed ID: 22821639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma.
    Kinoshita A; Onoda H; Imai N; Iwaku A; Oishi M; Tanaka K; Fushiya N; Koike K; Nishino H; Matsushima M
    Ann Surg Oncol; 2015 Mar; 22(3):803-10. PubMed ID: 25190127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-treatment C-reactive protein as a prognostic factor for recurrence after surgical resection of hepatocellular carcinoma.
    Nishikawa H; Arimoto A; Wakasa T; Kita R; Kimura T; Osaki Y
    Anticancer Res; 2013 Mar; 33(3):1181-8. PubMed ID: 23482800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE.
    Hucke F; Sieghart W; Pinter M; Graziadei I; Vogel W; Müller C; Heinzl H; Waneck F; Trauner M; Peck-Radosavljevic M
    J Hepatol; 2014 Jan; 60(1):118-26. PubMed ID: 24012941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The elevated C-reactive protein level is associated with poor prognosis in prostate cancer patients treated with radiotherapy.
    Thurner EM; Krenn-Pilko S; Langsenlehner U; Stojakovic T; Pichler M; Gerger A; Kapp KS; Langsenlehner T
    Eur J Cancer; 2015 Mar; 51(5):610-9. PubMed ID: 25618827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma.
    Hashimoto K; Ikeda Y; Korenaga D; Tanoue K; Hamatake M; Kawasaki K; Yamaoka T; Iwatani Y; Akazawa K; Takenaka K
    Cancer; 2005 May; 103(9):1856-64. PubMed ID: 15779015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognosis of untreated hepatocellular carcinoma.
    Giannini EG; Farinati F; Ciccarese F; Pecorelli A; Rapaccini GL; Di Marco M; Benvegnù L; Caturelli E; Zoli M; Borzio F; Chiaramonte M; Trevisani F;
    Hepatology; 2015 Jan; 61(1):184-90. PubMed ID: 25234419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors for long-term outcome after percutaneous thermal ablation for hepatocellular carcinoma: a survival analysis of 137 consecutive patients.
    Xu HX; Lu MD; Xie XY; Yin XY; Kuang M; Chen JW; Xu ZF; Liu GJ
    Clin Radiol; 2005 Sep; 60(9):1018-25. PubMed ID: 16124984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postoperative peak serum C-reactive protein predicts outcome of hepatic resection for hepatocellular carcinoma.
    Shiba H; Furukawa K; Fujiwara Y; Futagawa Y; Haruki K; Wakiyama S; Ishida Y; Misawa T; Yanaga K
    Anticancer Res; 2013 Feb; 33(2):705-9. PubMed ID: 23393371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
    Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
    J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.
    Wörns MA; Koch S; Niederle IM; Marquardt JU; Nguyen-Tat M; Gamstätter T; Schuchmann M; Schulze-Bergkamen H; Galle PR; Weinmann A
    Dig Liver Dis; 2013 May; 45(5):408-13. PubMed ID: 23182599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nationwide study of 4741 patients with non-B non-C hepatocellular carcinoma with special reference to the therapeutic impact.
    Utsunomiya T; Shimada M; Kudo M; Ichida T; Matsui O; Izumi N; Matsuyama Y; Sakamoto M; Nakashima O; Ku Y; Kokudo N; Makuuchi M;
    Ann Surg; 2014 Feb; 259(2):336-45. PubMed ID: 23673768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy.
    Shao YY; Wu CH; Lu LC; Chan SY; Ma YY; Yen FC; Hsu CH; Cheng AL
    J Hepatol; 2014 Feb; 60(2):313-8. PubMed ID: 24036008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of the albumin-bilirubin grade for predicting prognosis after curative resection of patients with early-stage hepatocellular carcinoma.
    Ma XL; Zhou JY; Gao XH; Tian L; Wu J; Zhang CY; Zhou Y; Dai Q; Wang BL; Pan BS; Yang XR; Guo W
    Clin Chim Acta; 2016 Nov; 462():15-22. PubMed ID: 27520748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated serum vitamin B(12) levels in association with tumor markers as the prognostic factors predictive for poor survival in patients with hepatocellular carcinoma.
    Lin CY; Kuo CS; Lu CL; Wu MY; Huang RF
    Nutr Cancer; 2010; 62(2):190-7. PubMed ID: 20099193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.